The Milan Biotech Startup You Need to Know About This Month: Why Nexus Therapeutics Is Reshaping Drug Development

Nestled in a converted warehouse on Via Pietro Maroncelli in the Porta Nuova district, Nexus Therapeutics has quietly become one of Milan's most consequential biotech ventures—and this month's €42 million Series B funding round proves the city's innovation ecosystem is maturing beyond software and fashion tech.

The company, founded in 2021 by a coalition of computational biologists and former pharmaceutical researchers, specialises in AI-driven drug discovery targeting rare genetic diseases. Their platform uses machine learning to identify molecular targets that traditional screening methods miss entirely, compressing what typically takes three to five years into eighteen months.

What makes Nexus particularly significant for Milan's tech narrative is its refusal to follow the well-trodden path of relocating to Cambridge or Basel. Instead, the 87-person team has invested heavily in Milan's emerging biotech corridor around Isocenter and the innovation hubs clustering near the Politecnico. Their choice reflects a broader trend: the city is attracting serious capital precisely because it offers lower operational costs (rent in Porta Nuova runs €15–22 per square metre annually, versus €40+ in central London) without sacrificing talent access.

The Series B round, led by Berlin-based HealthTech Capital with participation from Italian family offices and UK institutional investors, values the company at €220 million. More tellingly, it includes a €6 million commitment for expanding their Milan headquarters and establishing a dedicated computational centre at the Università degli Studi di Milano's life sciences campus.

Industry observers note that Nexus's success arrives at a critical moment. Italy's biotech sector has historically struggled with brain drain—talented researchers gravitating toward US or Swiss opportunities. But the combination of improved venture funding infrastructure, the EU's €95.5 billion Horizon Europe research budget, and post-pandemic interest in resilient supply chains is rebalancing incentives. Milan now hosts forty-three biotech and medtech startups backed by venture capital, up from twelve in 2019.

For the tech community watching Milan's evolution, Nexus exemplifies a maturing ecosystem: not just faster internet and collaborative spaces, but mission-driven ventures solving complex problems with global implications. Their next milestone—first-in-human trials on a rare neurological disorder, expected in early 2027—will test whether Milan can genuinely compete as a biotech destination.

That's the company reshaping how we think about Milan's innovation potential this month.

This article was compiled by AI and screened before publishing. See our editorial standards.